Published in Cancer Weekly, February 2nd, 1998
The systemic administration of IFN(alpha) has been shown to induce remission and prolong survival in some patients with chronic myelogenous leukemia (CML). J.D. Lutton, representing colleagues from The Rockefeller University, New York, presented data at the 39th Annual Meeting of the American Society of Hematology, held December 5-9, 1997, in San Diego, California, which suggested that the administration of CML cells modified to secrete IFN(alpha) might also be therapeutically advantageous (abstract "Retroviral Gene Transfer of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.